This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Bryan Poltilove
Operating Partner at BroadOak Capital Partners


As Operating Partner with BroadOak, Mr. Poltilove lead the firm’s investments in Cell and Gene Therapy as well as the related sectors of Bioproduction and Cell Biology.  Mr. Poltilove joined BroadOak after 12 years with Thermo Fisher Scientific where he served as Vice President and General Manager.  Mr. Poltilove built the company’s cell and gene therapy business which he grew organically at 50%+ CAGR and through acquisitions, including Brammer Bio.  Prior to Thermo Fisher, Mr. Poltilove served as Director of Revenue Strategy & Operations at the Corporate Executive Board and also held several commercial strategy roles with Johnson & Johnson.  He holds Bachelor’s degrees in Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an MBA from the J.L. Kellogg School of Management at Northwestern University.

Agenda Sessions

  • Panel Discussion: Investment View on Innovation in Cell & Gene Therapy: Trends, Technologies, and Early-Stage Success